This site is intended for healthcare professionals
UCB EHSF 2024
Advances in hidradenitis suppurativa
Declaration of sponsorship UCB Biopharma SRL

Surgery for HS

Declaration of sponsorship UCB Biopharma SRL
Last updated:30th Oct 2024
Published:20th Feb 2024

EADV 2024

A systematic review and meta-analysis highlighted variations in recurrence of hidradenitis suppurativa (HS) associated with different surgical methods.

Kaiyang Li (McGill University, Montréal, Québec, Canada) and team included 32 studies with over 8,000 procedures performed on 6,992 people with HS.

For excisional surgeries, wide local excision was associated with significant 43% and 50% reduced risks for recurrence relative to limited local excision and to incision and drainage, respectively. The number needed to treat with wide local excision to prevent one recurrence was six.

For wound closure methods, simple primary closure was associated with a 24% reduced recurrence risk relative to split-thickness skin grafting. There were no recurrence rate differences between the assessed healing methods.

Another study, from Antonio Martorell (Hospital de Manises, Valencia, Spain) and colleagues, demonstrated the benefits of ultrasound-guided surgery, with no recurrence found among 122 patients over an average 22 months of follow-up.

EHSF 2024

Surgery for HS

Watch Professor Falk Bechara discuss the use of surgery in hidradenitis suppurativa (HS), including his thoughts on when surgery should be performed and the short-term future of the treatment landscape.


Professor Falk Bechara discusses the use of surgery in HS, including when surgery should be performed and addressing barriers. View transcript.


“After surgery, the story is not over.” Professor Bechara discusses recurrence in people with HS and offers his thoughts on areas of surgical treatment requiring further research. View transcript.

Professor Bechara shares his thoughts on the short-term future of the treatment landscape and stresses the importance of education in HS. View transcript.

Welcome: